Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CTSE | P14091 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412012 | 0.85 | RAB9A (0.41) | CTSSLMNASMN1; SMN2TSHRHTT | |
| SCHEMBL5513715 | 0.85 | RAB9A (0.41) | CTSSLMNASMN1; SMN2TSHRHTT | |
| SCHEMBL5421407 | 0.85 | RAB9A (0.41) | CTSSLMNASMN1; SMN2TSHRHTT | |
| SCHEMBL6206025 | 0.82 | MAPT (0.39) | RENCTSSAAK1MAPT | |
| SCHEMBL6206918 | 0.82 | METAP2 (0.40) | CTSSLMNASMN1; SMN2TSHRHTT | |
| SCHEMBL6206021 | 0.81 | CTSS (0.40) | RENCTSSAAK1CTSLLMNA | |
| SCHEMBL6415412 | 0.78 | NPC1 (0.35) | SMN1; SMN2MAPT | |
| SCHEMBL5736600 | 0.78 | NPC1 (0.42) | CTSSCTSLLMNASMN1; SMN2TSHR | |
| SCHEMBL5736602 | 0.78 | NPC1 (0.42) | CTSSCTSLLMNASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL5946008 | 0.77 | CTSS (0.42) | RENCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288336-A1 | Cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288336-A1 | Cysteine protease inhibitors | CTSF, CTSS, CTSB | REN 403/4885CTSS 2/4885AAK1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.